Apis Mellifera Arnica Montana Bellis Perennis Bryo

證據等級: L5

預測適應症: 0 個

Multi-Ingredient Homeopathic Formula: Insufficient Evidence for TxGNN Repurposing Assessment

One-Sentence Summary

This Evidence Pack describes a 20-ingredient homeopathic combination formula (including Arnica montana, Calendula officinalis, Hypericum perforatum, and Echinacea, among others), with no established original indication and no market authorization in Taiwan. The TxGNN model was unable to generate predicted indications for this candidate, as the multi-component structure without a single DrugBank ID prevents knowledge-graph traversal. With 0 clinical trials and 0 publications attributable to this specific formulation via the TxGNN pipeline, no meaningful repurposing evaluation can be conducted at this stage.

Quick Overview

Item	Content
Original Indication	Not established (no market authorization)
Predicted New Indication	None generated
TxGNN Prediction Score	N/A
Evidence Level	L5 — No predictions generated
Market Status	Not marketed (Taiwan)
Number of NDAs	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

No new indication was predicted by TxGNN, so this section departs from the standard format to explain the root cause.

This formula lists 20 co-ingredients spanning botanical and mineral sources typically associated with homeopathic preparations for musculoskeletal trauma, bruising, and inflammation — among them Arnica montana, Calendula officinalis, Comfrey root, Ruta graveolens, Hamamelis virginiana, Bryonia alba, and Hypericum perforatum. However, no single DrugBank ID could be assigned to the formula as a whole, which means no drug node exists in the TxGNN knowledge graph for scoring.

TxGNN is architecturally designed to evaluate individual chemical entities or single active pharmaceutical ingredients. A co-listed formula of 20 ingredients — each potentially at homeopathic dilutions — cannot be resolved to a single graph node, making drug–disease traversal impossible under the current pipeline. Until the formula is either (a) decomposed into individually evaluable constituents or (b) matched to a branded product with an established regulatory identifier, TxGNN prediction scores cannot be generated.

Clinical Trial Evidence

Currently no related clinical trials registered through the TxGNN evidence pipeline for this candidate.

Note: Individual constituent herbs such as Arnica montana, Echinacea, and Hypericum perforatum have independent clinical literature, but those studies are not attributable to this specific multi-ingredient formulation and were not retrieved by the pipeline.

Literature Evidence

Currently no related literature available through the TxGNN evidence pipeline for this candidate.

Market Information

This product has no Taiwan market authorization. No NDA or equivalent license records were identified in the TFDA database (query returned 0 results).

Safety Considerations

Please refer to the package insert for safety information.

Note: No DDI data was retrievable, and no package insert warnings or contraindications were available. Several individual components carry known safety signals that would require evaluation in any future assessment — notably Comfrey root (pyrrolizidine alkaloids, hepatotoxicity risk), Goldenseal (CYP inhibition), and Toxicodendron pubescens (contact sensitizer).

Conclusion and Next Steps

Decision: Hold

Rationale: This multi-ingredient homeopathic formula lacks a DrugBank ID, has no approved indications, and generated zero TxGNN predictions — making a repurposing evaluation impossible under the current framework without substantial data remediation.

To proceed, the following is needed:

Identify the branded product name — If this formula corresponds to a known product (e.g., Traumeel®, Zeel®, or a regional homeopathic brand), re-run the pipeline using that product’s regulatory identifier or DrugBank entry
Resolve DG001 (Blocking): Obtain the TFDA or originator package insert to extract approved indications, warnings, and contraindications
Resolve DG002 (High): Determine whether individual active constituents have DrugBank records (e.g., Arnica montana, Hypericum perforatum, Matricaria chamomilla) and evaluate them separately within TxGNN
Clarify formulation type: Confirm whether this is a registered homeopathic medicine, an herbal supplement, or a botanical drug — as regulatory pathway and evidence standards differ substantially
Assess individual ingredients: Components like Hypericum perforatum and Echinacea have published clinical evidence; a constituent-level repurposing analysis may be feasible even if the combined formula cannot currently be processed
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.